Ensign Peak Advisors
DNLI icon

Ensign Peak Advisors’s Denali Therapeutics DNLI Stock Holding History

Ensign Peak Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
582,669
+66,948
+13% +$1.38M 0.02% 372
2026
Q1 		$9.9M Hold
515,721
– – 0.02% 412
2025
Q4 		$8.51M Sell
515,721
-18,350
-3% -$310K 0.02% 439
2025
Q3 		$7.75M Buy
534,071
+60,376
+13% +$868K 0.01% 505
2025
Q2 		$6.63M Sell
473,695
-114,090
-19% -$1.61M 0.01% 579
2025
Q1 		$7.99M Buy
587,785
+241,481
+70% +$4.63M 0.02% 521
2024
Q4 		$7.06M Hold
346,304
– – 0.01% 559
2024
Q3 		$10.1M Hold
346,304
– – 0.02% 467
2024
Q2 		$8.04M Hold
346,304
– – 0.01% 508
2024
Q1 		$7.11M Sell
346,304
-2,193
-0.6% -$41.2K 0.01% 537
2023
Q4 		$7.48M Hold
348,497
– – 0.01% 519
2023
Q3 		$7.19M Buy
348,497
+200,000
+135% +$5.07M 0.02% 475
2023
Q2 		$4.38M Buy
148,497
+3,950
+3% +$111K 0.01% 622
2023
Q1 		$3.33M Buy
144,547
+2,000
+1% +$55K 0.01% 676
2022
Q4 		$3.96M Buy
142,547
+19,900
+16% +$592K 0.01% 612
2022
Q3 		$3.76M Buy
122,647
+36,975
+43% +$1.2M 0.01% 595
2022
Q2 		$2.52M Sell
85,672
-18,904
-18% -$495K 0.01% 718
2022
Q1 		$3.37M Buy
104,576
+120
+0.1% +$4.13K 0.01% 701
2021
Q4 		$4.66M Buy
104,456
+38,108
+57% +$1.81M 0.01% 684
2021
Q3 		$3.35M Buy
66,348
+24,406
+58% +$1.38M 0.01% 825
2021
Q2 		$3.29M Buy
41,942
+300
+0.7% +$18.6K 0.01% 833
2021
Q1 		$2.38M Sell
41,642
-16,280
-28% -$1.09M 0.01% 1021
2020
Q4 		$4.85M Buy
57,922
+201
+0.3% +$12.2K 0.01% 619
2020
Q3 		$2.07M Buy
57,721
+414
+0.7% +$12.5K 0.01% 955
2020
Q2 		$1.39M Sell
57,307
-67,842
-54% -$1.6M ﹤0.01% 1153
2020
Q1 		$2.19M Buy
125,149
+117,173
+1,469% +$2.44M 0.01% 791
2019
Q4 		$139K Buy
+7,976
New +$133K ﹤0.01% 1635

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's DNLI Position: Q2 2026 in Review

Ensign Peak Advisors increased its Denali Therapeutics (DNLI) stake by 13% in Q2 2026, buying an estimated $1.38M and bringing the position to 582,669 shares worth $15M. The position accounts for 0.02% of the portfolio, ranked #372.

Ensign Peak Advisors first reported a position in DNLI in Q4 2019 and has held it in 27 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Ensign Peak Advisors held 582,669 shares of Denali Therapeutics worth $15M as of Q2 2026.
  • Ensign Peak Advisors bought 66,948 Denali Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Denali Therapeutics made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #372 holding.
  • Ensign Peak Advisors first reported a position in Denali Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.